Vir Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Vir Biotechnology has a total shareholder equity of $1.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $257.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$914.47m |
| Equity | US$1.24b |
| Total liabilities | US$257.63m |
| Total assets | US$1.50b |
Recent financial health updates
Recent updates
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Dec 13Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Nov 05Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
Nov 04
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Sep 08Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Financial Position Analysis
Short Term Liabilities: VIR's short term assets ($1.0B) exceed its short term liabilities ($117.2M).
Long Term Liabilities: VIR's short term assets ($1.0B) exceed its long term liabilities ($140.5M).
Debt to Equity History and Analysis
Debt Level: VIR is debt free.
Reducing Debt: VIR had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIR has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 0.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 11:57 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |